<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;ff=20240920061119&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;ff=20240920061119&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 20 Sep 2024 10:11:20 +0000</lastbuilddate>
<pubDate>Thu, 19 Sep 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>TEER is non-inferior to surgery in patients with secondary mitral regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39300252/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240920061119&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 19. doi: 10.1038/s41569-024-01089-9. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39300252/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">39300252</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01089-9>10.1038/s41569-024-01089-9</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39300252</guid>
<pubDate>Thu, 19 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2024-09-19</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>TEER is non-inferior to surgery in patients with secondary mitral regurgitation</dc:title>
<dc:identifier>pmid:39300252</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01089-9</dc:identifier>
</item>
<item>
<title>Finerenone improves outcomes in HFmrEF and HFpEF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39300251/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240920061119&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 19. doi: 10.1038/s41569-024-01087-x. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39300251/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">39300251</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01087-x>10.1038/s41569-024-01087-x</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39300251</guid>
<pubDate>Thu, 19 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2024-09-19</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Finerenone improves outcomes in HFmrEF and HFpEF</dc:title>
<dc:identifier>pmid:39300251</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01087-x</dc:identifier>
</item>
<item>
<title>Benefit of vutrisiran in transthyretin amyloidosis with cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39300250/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240920061119&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 19. doi: 10.1038/s41569-024-01086-y. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39300250/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">39300250</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01086-y>10.1038/s41569-024-01086-y</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39300250</guid>
<pubDate>Thu, 19 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2024-09-19</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Benefit of vutrisiran in transthyretin amyloidosis with cardiomyopathy</dc:title>
<dc:identifier>pmid:39300250</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01086-y</dc:identifier>
</item>
<item>
<title>Combining TAVI with PCI in patients with aortic stenosis and CAD</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39300249/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240920061119&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 19. doi: 10.1038/s41569-024-01080-4. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39300249/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">39300249</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01080-4>10.1038/s41569-024-01080-4</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39300249</guid>
<pubDate>Thu, 19 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2024-09-19</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Combining TAVI with PCI in patients with aortic stenosis and CAD</dc:title>
<dc:identifier>pmid:39300249</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01080-4</dc:identifier>
</item>
<item>
<title>Prognostic value of ventricular arrhythmia in early post-infarction left ventricular dysfunction: the French nationwide WICD-MI study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39299922/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240920061119&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with LVEF ≤ 35%, sustained VA during the early post-infarction phase is predictive of recurrent sustained VAs and 1-year mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 20:ehae575. doi: 10.1093/eurheartj/ehae575. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Prophylactic implantable cardioverter-defibrillators (ICDs) are not recommended until left ventricular ejection fraction (LVEF) has been reassessed 40 to 90 days after an acute myocardial infarction. In the current therapeutic era, the prognosis of sustained ventricular arrhythmias (VAs) occurring during this early post-infarction phase (i.e. within 3 months of hospital discharge) has not yet been specifically evaluated in post-myocardial infarction patients with impaired LVEF. Such was the aim of this retrospective study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Data analysis was based on a nationwide registry of 1032 consecutive patients with LVEF ≤ 35% after acute myocardial infarction who were implanted with an ICD after being prescribed a wearable cardioverter-defibrillator (WCD) for a period of 3 months upon discharge from hospital after the index infarction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: ICDs were implanted either because a sustained VA occurred while on WCD (VA+/WCD, n = 72) or because LVEF remained ≤35% at the end of the early post-infarction phase (VA-/WCD, n = 960). The median follow-up was 30.9 months. Sustained VAs occurred within 1 year after ICD implantation in 22.2% and 3.5% of VA+/WCD and VA-/WCD patients, respectively (P &lt; .0001). The adjusted multivariable analysis showed that sustained VAs while on WCD independently predicted recurrence of sustained VAs at 1 year (adjusted hazard ratio [HR] 6.91; 95% confidence interval [CI] 3.73-12.81; P &lt; .0001) and at the end of follow-up (adjusted HR 3.86; 95% CI 2.37-6.30; P &lt; .0001) as well as 1-year mortality (adjusted HR 2.86; 95% CI 1.28-6.39; P = .012).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with LVEF ≤ 35%, sustained VA during the early post-infarction phase is predictive of recurrent sustained VAs and 1-year mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39299922/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">39299922</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae575>10.1093/eurheartj/ehae575</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39299922</guid>
<pubDate>Thu, 19 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Mathieu Echivard</dc:creator>
<dc:creator>Jean-Marc Sellal</dc:creator>
<dc:creator>Chloé Ziliox</dc:creator>
<dc:creator>Eloi Marijon</dc:creator>
<dc:creator>Pierre Bordachar</dc:creator>
<dc:creator>Sylvain Ploux</dc:creator>
<dc:creator>Karim Benali</dc:creator>
<dc:creator>Christelle Marquié</dc:creator>
<dc:creator>Clémence Docq</dc:creator>
<dc:creator>Didier Klug</dc:creator>
<dc:creator>Romain Eschalier</dc:creator>
<dc:creator>Baptiste Maille</dc:creator>
<dc:creator>Jean-Claude Deharo</dc:creator>
<dc:creator>Dominique Babuty</dc:creator>
<dc:creator>Thibaud Genet</dc:creator>
<dc:creator>Estelle Gandjbakhch</dc:creator>
<dc:creator>Antoine Da Costa</dc:creator>
<dc:creator>Olivier Piot</dc:creator>
<dc:creator>Damien Minois</dc:creator>
<dc:creator>Jean-Baptiste Gourraud</dc:creator>
<dc:creator>Pierre Mondoly</dc:creator>
<dc:creator>Philippe Maury</dc:creator>
<dc:creator>Serge Boveda</dc:creator>
<dc:creator>Jean-Luc Pasquié</dc:creator>
<dc:creator>Raphaël Martins</dc:creator>
<dc:creator>Christophe Leclercq</dc:creator>
<dc:creator>Charles Guenancia</dc:creator>
<dc:creator>Gabriel Laurent</dc:creator>
<dc:creator>Mathieu Becker</dc:creator>
<dc:creator>Julien Bertrand</dc:creator>
<dc:creator>Philippe Chevalier</dc:creator>
<dc:creator>Vladimir Manenti</dc:creator>
<dc:creator>Maciej Kubala</dc:creator>
<dc:creator>Pascal Defaye</dc:creator>
<dc:creator>Peggy Jacon</dc:creator>
<dc:creator>Antoine Desbiolles</dc:creator>
<dc:creator>Marc Badoz</dc:creator>
<dc:creator>Laurence Jesel</dc:creator>
<dc:creator>Nicolas Lellouche</dc:creator>
<dc:creator>Paul-Ursmar Milliez</dc:creator>
<dc:creator>Paul Ollitrault</dc:creator>
<dc:creator>Samir Fareh</dc:creator>
<dc:creator>Matthieu Bercker</dc:creator>
<dc:creator>Jacques Mansourati</dc:creator>
<dc:creator>Benoît Guy-Moyat</dc:creator>
<dc:creator>Jean-Pierre Chabert</dc:creator>
<dc:creator>Nicolas Luconi</dc:creator>
<dc:creator>Pierre-François Winum</dc:creator>
<dc:creator>Frédéric Anselme</dc:creator>
<dc:creator>Fabrice Extramiana</dc:creator>
<dc:creator>Camille Delahaye</dc:creator>
<dc:creator>François Jourda</dc:creator>
<dc:creator>Olivier Bizeau</dc:creator>
<dc:creator>Mathieu Nasarre</dc:creator>
<dc:creator>Arnaud Olivier</dc:creator>
<dc:creator>Stéphane Fromentin</dc:creator>
<dc:creator>Thibault Villemin</dc:creator>
<dc:creator>Olivier Levavasseur</dc:creator>
<dc:creator>Néfissa Hammache</dc:creator>
<dc:creator>Isabelle Magnin-Poull</dc:creator>
<dc:creator>Hugues Blangy</dc:creator>
<dc:creator>Nicolas Sadoul</dc:creator>
<dc:creator>Kevin Duarte</dc:creator>
<dc:creator>Nicolas Girerd</dc:creator>
<dc:creator>Christian de Chillou</dc:creator>
<dc:date>2024-09-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Prognostic value of ventricular arrhythmia in early post-infarction left ventricular dysfunction: the French nationwide WICD-MI study</dc:title>
<dc:identifier>pmid:39299922</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae575</dc:identifier>
</item>
<item>
<title>The quest for the holy grail in antithrombotic therapy: revitalized hope for platelet GPVI as a safe and effective antithrombotic target</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39299915/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240920061119&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 20:ehae592. doi: 10.1093/eurheartj/ehae592. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39299915/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">39299915</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae592>10.1093/eurheartj/ehae592</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39299915</guid>
<pubDate>Thu, 19 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>James D McFadyen</dc:creator>
<dc:creator>Xiaowei Wang</dc:creator>
<dc:creator>Karlheinz Peter</dc:creator>
<dc:date>2024-09-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The quest for the holy grail in antithrombotic therapy: revitalized hope for platelet GPVI as a safe and effective antithrombotic target</dc:title>
<dc:identifier>pmid:39299915</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae592</dc:identifier>
</item>
<item>
<title>High-resolution functional mapping of RAD51C by saturation genome editing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39299233/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240920061119&amp;v=2.18.0.post9+e462414
      <description>Pathogenic variants in RAD51C confer an elevated risk of breast and ovarian cancer, while individuals homozygous for specific RAD51C alleles may develop Fanconi anemia. Using saturation genome editing (SGE), we functionally assess 9,188 unique variants, including >;99.5% of all possible coding sequence single-nucleotide alterations. By computing changes in variant abundance and Gaussian mixture modeling (GMM), we functionally classify 3,094 variants to be disruptive and use clinical truth sets to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 16:S0092-8674(24)00968-1. doi: 10.1016/j.cell.2024.08.039. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Pathogenic variants in RAD51C confer an elevated risk of breast and ovarian cancer, while individuals homozygous for specific RAD51C alleles may develop Fanconi anemia. Using saturation genome editing (SGE), we functionally assess 9,188 unique variants, including >;99.5% of all possible coding sequence single-nucleotide alterations. By computing changes in variant abundance and Gaussian mixture modeling (GMM), we functionally classify 3,094 variants to be disruptive and use clinical truth sets to reveal an accuracy/concordance of variant classification >;99.9%. Cell fitness was the primary assay readout allowing us to observe a phenomenon where specific missense variants exhibit distinct depletion kinetics potentially suggesting that they represent hypomorphic alleles. We further explored our exhaustive functional map, revealing critical residues on the RAD51C structure and resolving variants found in cancer-segregating kindred. Furthermore, through interrogation of UK Biobank and a large multi-center ovarian cancer cohort, we find significant associations between SGE-depleted variants and cancer diagnoses.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39299233/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">39299233</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.039>10.1016/j.cell.2024.08.039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39299233</guid>
<pubDate>Thu, 19 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Rebeca Olvera-León</dc:creator>
<dc:creator>Fang Zhang</dc:creator>
<dc:creator>Victoria Offord</dc:creator>
<dc:creator>Yajie Zhao</dc:creator>
<dc:creator>Hong Kee Tan</dc:creator>
<dc:creator>Prashant Gupta</dc:creator>
<dc:creator>Tuya Pal</dc:creator>
<dc:creator>Carla Daniela Robles-Espinoza</dc:creator>
<dc:creator>Fernanda G Arriaga-González</dc:creator>
<dc:creator>Larissa Satiko Alcantara Sekimoto Matsuyama</dc:creator>
<dc:creator>Erwan Delage</dc:creator>
<dc:creator>Ed Dicks</dc:creator>
<dc:creator>Suzana Ezquina</dc:creator>
<dc:creator>Charlie F Rowlands</dc:creator>
<dc:creator>Clare Turnbull</dc:creator>
<dc:creator>Paul Pharoah</dc:creator>
<dc:creator>John R B Perry</dc:creator>
<dc:creator>Maria Jasin</dc:creator>
<dc:creator>Andrew J Waters</dc:creator>
<dc:creator>David J Adams</dc:creator>
<dc:date>2024-09-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>High-resolution functional mapping of RAD51C by saturation genome editing</dc:title>
<dc:identifier>pmid:39299233</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.039</dc:identifier>
</item>
<item>
<title>Non-Contractile Stem Cell-Cardiomyocytes Preserve Post-Infarction Heart Function</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39297201/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240920061119&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 19. doi: 10.1161/CIRCRESAHA.124.325133. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39297201/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">39297201</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325133>10.1161/CIRCRESAHA.124.325133</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39297201</guid>
<pubDate>Thu, 19 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Elaheh Karbassi</dc:creator>
<dc:creator>Dasom Yoo</dc:creator>
<dc:creator>Amy M Martinson</dc:creator>
<dc:creator>Xiulan Yang</dc:creator>
<dc:creator>Hans Reinecke</dc:creator>
<dc:creator>Michael Regnier</dc:creator>
<dc:creator>Charles E Murry</dc:creator>
<dc:date>2024-09-19</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Non-Contractile Stem Cell-Cardiomyocytes Preserve Post-Infarction Heart Function</dc:title>
<dc:identifier>pmid:39297201</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325133</dc:identifier>
</item>
<item>
<title>Management of Patients With Cardiac Arrest Requiring Interfacility Transport: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39297198/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240920061119&amp;v=2.18.0.post9+e462414
      <description>People who experience out-of-hospital cardiac arrest often require care at a regional center for continued treatment after resuscitation, but many do not initially present to the hospital where they will be admitted. For patients who require interfacility transport after cardiac arrest, the decision to transfer between centers is complex and often based on individual clinical characteristics, resources at the presenting hospital, and available transport resources. Once the decision has been made...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 19. doi: 10.1161/CIR.0000000000001282. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">People who experience out-of-hospital cardiac arrest often require care at a regional center for continued treatment after resuscitation, but many do not initially present to the hospital where they will be admitted. For patients who require interfacility transport after cardiac arrest, the decision to transfer between centers is complex and often based on individual clinical characteristics, resources at the presenting hospital, and available transport resources. Once the decision has been made to transfer a patient after cardiac arrest, there is little direct guidance on how best to provide interfacility transport. Accepting centers depend on transferring emergency departments and emergency medical services professionals to make important and nuanced decisions about postresuscitation care that may determine the efficacy of future treatments. The consequences of early care are greater when transport delays occur, which is common in rural areas or due to inclement weather. Challenges of providing interfacility transfer services for patients who have experienced cardiac arrest include varying expertise of clinicians, differing resources available to them, and nonstandardized communication between transferring and receiving centers. Although many aspects of care are insufficiently studied to determine implications for specific out-of-hospital treatment on outcomes, a general approach of maintaining otherwise recommended postresuscitation care during interfacility transfer is reasonable. This includes close attention to airway, vascular access, ventilator management, sedation, cardiopulmonary monitoring, antiarrhythmic treatments, blood pressure control, temperature control, and metabolic management. Patient stability for transfer, equity and inclusion, and communication also must be considered. Many of these aspects can be delivered by protocol-driven care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39297198/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">39297198</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001282>10.1161/CIR.0000000000001282</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39297198</guid>
<pubDate>Thu, 19 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Teresa L May</dc:creator>
<dc:creator>Erin A Bressler</dc:creator>
<dc:creator>Rebecca E Cash</dc:creator>
<dc:creator>Francis X Guyette</dc:creator>
<dc:creator>Steve Lin</dc:creator>
<dc:creator>Nicholas A Morris</dc:creator>
<dc:creator>Ashish R Panchal</dc:creator>
<dc:creator>Stacy M Perrin</dc:creator>
<dc:creator>Melissa Vogelsong</dc:creator>
<dc:creator>Joyce Yeung</dc:creator>
<dc:creator>Jonathan Elmer</dc:creator>
<dc:creator>American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Clinical Cardiology; and Council on Cardiovascular and Stroke Nursing</dc:creator>
<dc:date>2024-09-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Management of Patients With Cardiac Arrest Requiring Interfacility Transport: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:39297198</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001282</dc:identifier>
</item>
<item>
<title>If We Measure, We Can Improve</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39293888/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240920061119&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 24;84(13):1276-1278. doi: 10.1016/j.jacc.2024.07.031.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39293888/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">39293888</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.031>10.1016/j.jacc.2024.07.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39293888</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Celina M Yong</dc:creator>
<dc:creator>Sanket S Dhruva</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>If We Measure, We Can Improve</dc:title>
<dc:identifier>pmid:39293888</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.031</dc:identifier>
</item>
<item>
<title>Low-Density Lipoprotein Cholesterol Control as a Performance Measure: A National Analysis of the VHA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39293887/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240920061119&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 24;84(13):1272-1275. doi: 10.1016/j.jacc.2024.07.025.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39293887/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">39293887</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.025>10.1016/j.jacc.2024.07.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39293887</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Sneha S Jain</dc:creator>
<dc:creator>Megan Skye</dc:creator>
<dc:creator>Natasha Din</dc:creator>
<dc:creator>Adam Furst</dc:creator>
<dc:creator>David J Maron</dc:creator>
<dc:creator>Paul Heidenreich</dc:creator>
<dc:creator>Neil Kalwani</dc:creator>
<dc:creator>Ankeet S Bhatt</dc:creator>
<dc:creator>Alexander T Sandhu</dc:creator>
<dc:creator>Fatima Rodriguez</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Low-Density Lipoprotein Cholesterol Control as a Performance Measure: A National Analysis of the VHA</dc:title>
<dc:identifier>pmid:39293887</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.025</dc:identifier>
</item>
<item>
<title>Stopping Trials Early for Benefit: Insights From Recent Pivotal Trials in Chronic Kidney Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39293886/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240920061119&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 24;84(13):1268-1271. doi: 10.1016/j.jacc.2024.07.026.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39293886/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">39293886</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.026>10.1016/j.jacc.2024.07.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39293886</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Sanjay Kaul</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Stopping Trials Early for Benefit: Insights From Recent Pivotal Trials in Chronic Kidney Disease</dc:title>
<dc:identifier>pmid:39293886</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.026</dc:identifier>
</item>
<item>
<title>Treatment of OSA and its Impact on Cardiovascular Disease, Part 2: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39293885/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240920061119&amp;v=2.18.0.post9+e462414
      <description>Many studies have shown an association of obstructive sleep apnea (OSA) with incident cardiovascular diseases, particularly when comorbid with insomnia, excessive sleepiness, obesity hypoventilation syndrome, and chronic obstructive pulmonary disease. Randomized controlled trials (RCTs) have demonstrated that treatment of OSA with positive airway pressure devices (CPAP) improves systemic hypertension, particularly in those with resistant hypertension who are adherent to CPAP. However, large RCTs...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 24;84(13):1224-1240. doi: 10.1016/j.jacc.2024.07.024.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Many studies have shown an association of obstructive sleep apnea (OSA) with incident cardiovascular diseases, particularly when comorbid with insomnia, excessive sleepiness, obesity hypoventilation syndrome, and chronic obstructive pulmonary disease. Randomized controlled trials (RCTs) have demonstrated that treatment of OSA with positive airway pressure devices (CPAP) improves systemic hypertension, particularly in those with resistant hypertension who are adherent to CPAP. However, large RCTs have not shown long-term benefits of CPAP on hard cardiovascular outcomes, but post hoc analyses of these RCTs have demonstrated improved hard outcomes in those who use CPAP adequately. In theory, low CPAP adherence and patient selection may have contributed to neutral results in intention-to-treat analyses. Only by further research into clinical, translational, and basic underlying mechanisms is major progress likely to continue. This review highlights the various treatment approaches for sleep disorders, particularly OSA comorbid with various other disorders, the potential reasons for null results of RCTs treating OSA with CPAP, and suggested approaches for future trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39293885/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">39293885</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.024>10.1016/j.jacc.2024.07.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39293885</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Shahrokh Javaheri</dc:creator>
<dc:creator>Sogol Javaheri</dc:creator>
<dc:creator>David Gozal</dc:creator>
<dc:creator>Francisco Campos-Rodriguez</dc:creator>
<dc:creator>Miguel Angel Martinez-Garcia</dc:creator>
<dc:creator>Babak Mokhlesi</dc:creator>
<dc:creator>Reena Mehra</dc:creator>
<dc:creator>Walter T McNicholas</dc:creator>
<dc:creator>Virend K Somers</dc:creator>
<dc:creator>Phyllis C Zee</dc:creator>
<dc:creator>Peter Cistulli</dc:creator>
<dc:creator>Atul Malhotra</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Treatment of OSA and its Impact on Cardiovascular Disease, Part 2: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:39293885</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.024</dc:identifier>
</item>
<item>
<title>Interactions of Obstructive Sleep Apnea With the Pathophysiology of Cardiovascular Disease, Part 1: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39293884/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240920061119&amp;v=2.18.0.post9+e462414
      <description>The American Heart Association considers sleep health an essential component of cardiovascular health, and sleep is generally a time of cardiovascular quiescence, such that any deviation from normal sleep may be associated with adverse cardiovascular consequences. Many studies have shown that both impaired quantity and quality of sleep, particularly with obstructive sleep apnea (OSA) and comorbid sleep disorders, are associated with incident cardiometabolic consequences. OSA is associated with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 24;84(13):1208-1223. doi: 10.1016/j.jacc.2024.02.059.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The American Heart Association considers sleep health an essential component of cardiovascular health, and sleep is generally a time of cardiovascular quiescence, such that any deviation from normal sleep may be associated with adverse cardiovascular consequences. Many studies have shown that both impaired quantity and quality of sleep, particularly with obstructive sleep apnea (OSA) and comorbid sleep disorders, are associated with incident cardiometabolic consequences. OSA is associated with repetitive episodes of altered blood gases, arousals, large negative swings in intrathoracic pressures, and increased sympathetic activity. Recent studies show that OSA is also associated with altered gut microbiota, which could contribute to increased risk of cardiovascular disease. OSA has been associated with hypertension, atrial fibrillation, heart failure, coronary artery disease, stroke, and excess cardiovascular mortality. Association of OSA with chronic obstructive lung disease (overlap syndrome) and morbid obesity (obesity hypoventilation syndrome) increases the odds of mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39293884/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">39293884</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.059>10.1016/j.jacc.2024.02.059</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39293884</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Shahrokh Javaheri</dc:creator>
<dc:creator>Sogol Javaheri</dc:creator>
<dc:creator>Virend K Somers</dc:creator>
<dc:creator>David Gozal</dc:creator>
<dc:creator>Babak Mokhlesi</dc:creator>
<dc:creator>Reena Mehra</dc:creator>
<dc:creator>Walter T McNicholas</dc:creator>
<dc:creator>Phyllis C Zee</dc:creator>
<dc:creator>Francisco Campos-Rodriguez</dc:creator>
<dc:creator>Miguel Angel Martinez-Garcia</dc:creator>
<dc:creator>Peter Cistulli</dc:creator>
<dc:creator>Atul Malhotra</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Interactions of Obstructive Sleep Apnea With the Pathophysiology of Cardiovascular Disease, Part 1: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:39293884</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.059</dc:identifier>
</item>
<item>
<title>Takotsubo Cardiomyopathy: New Insights Into Long-Term Outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39293883/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240920061119&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 24;84(13):1175-1177. doi: 10.1016/j.jacc.2024.05.074.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39293883/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">39293883</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.074>10.1016/j.jacc.2024.05.074</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39293883</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Peter S Rahko</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Takotsubo Cardiomyopathy: New Insights Into Long-Term Outcomes</dc:title>
<dc:identifier>pmid:39293883</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.074</dc:identifier>
</item>
<item>
<title>Recovery of Left Ventricular Function and Long-Term Outcomes in Patients With Takotsubo Syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39293882/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240920061119&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Late recovery of LV function after TTS is associated with reduced short- and long-term survival. In TTS patients without early LV recovery, closer clinical follow-up might be considered.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 24;84(13):1163-1174. doi: 10.1016/j.jacc.2024.05.075.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Takotsubo syndrome (TTS) is a form of transient left ventricular (LV) dysfunction that usually resolves within days to weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We aimed to assess the predictors and prognostic impact of time-to-LV recovery after TTS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Prospective serial imaging data from the nationwide, multicenter RETAKO (REgistry on TAKOtsubo Syndrome) were comprehensively reviewed to assess the timing of LV recovery. Multivariable logistic regression was used to assess factors associated with late (≥10 days) vs early (&lt;10 days) recovery. The long-term risk of all-cause mortality was compared between the late and early recovery groups using fully adjusted Cox models, and using flexible parametric survival models with recovery time included as a continuous variable.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 1,463 patients included (median age 73 years, 13% men), 373 (25%) had late and 1,090 (75%) had early LV recovery. Older age, history of neurological disorders, bystander coronary artery disease, active cancer, physical triggers, elevated inflammatory biomarkers, cardiogenic shock, and lower LV ejection fraction at admission were independent predictors of late recovery. At 4-year follow-up, the adjusted risk of death was significantly higher in patients with late recovery compared with those with early recovery (16.0% vs 8.6%, adjusted HR: 1.31; 95% CI: 1.12-1.60), with the risk of death increasing by 8% for every additional 10-day delay in time-to-LV recovery (adjusted HR: 1.08; 95% CI: 1.04-1.13).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Late recovery of LV function after TTS is associated with reduced short- and long-term survival. In TTS patients without early LV recovery, closer clinical follow-up might be considered.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39293882/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">39293882</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.075>10.1016/j.jacc.2024.05.075</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39293882</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Manuel Almendro-Delia</dc:creator>
<dc:creator>Luis López-Flores</dc:creator>
<dc:creator>Aitor Uribarri</dc:creator>
<dc:creator>Oscar Vedia</dc:creator>
<dc:creator>Emilia Blanco-Ponce</dc:creator>
<dc:creator>María Del Carmen López-Flores</dc:creator>
<dc:creator>Antonio P Rivas-García</dc:creator>
<dc:creator>Clara Fernández-Cordón</dc:creator>
<dc:creator>Alessandro Sionis</dc:creator>
<dc:creator>Agustín C Martín-García</dc:creator>
<dc:creator>Ravi Vazirani</dc:creator>
<dc:creator>Miguel Corbí-Pascual</dc:creator>
<dc:creator>Jorge Salamanca</dc:creator>
<dc:creator>Alberto Pérez-Castellanos</dc:creator>
<dc:creator>Manuel Martínez</dc:creator>
<dc:creator>Víctor Manuel Becerra</dc:creator>
<dc:creator>David Aritza-Conty</dc:creator>
<dc:creator>Javier López-País</dc:creator>
<dc:creator>Marta Guillén-Marzo</dc:creator>
<dc:creator>Carmen Lluch-Requerey</dc:creator>
<dc:creator>Juan C García-Rubira</dc:creator>
<dc:creator>Iván J Núñez-Gil</dc:creator>
<dc:creator>RETAKO Investigators</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Recovery of Left Ventricular Function and Long-Term Outcomes in Patients With Takotsubo Syndrome</dc:title>
<dc:identifier>pmid:39293882</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.075</dc:identifier>
</item>
<item>
<title>In vivo DNA replication dynamics unveil aging-dependent replication stress</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39293447/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240920061119&amp;v=2.18.0.post9+e462414
      <description>The genome duplication program is affected by multiple factors in vivo, including developmental cues, genotoxic stress, and aging. Here, we monitored DNA replication initiation dynamics in regenerating livers of young and old mice after partial hepatectomy to investigate the impact of aging. In young mice, the origin firing sites were well defined; the majority were located 10-50 kb upstream or downstream of expressed genes, and their position on the genome was conserved in human cells. Old mice...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 10:S0092-8674(24)00963-2. doi: 10.1016/j.cell.2024.08.034. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The genome duplication program is affected by multiple factors in vivo, including developmental cues, genotoxic stress, and aging. Here, we monitored DNA replication initiation dynamics in regenerating livers of young and old mice after partial hepatectomy to investigate the impact of aging. In young mice, the origin firing sites were well defined; the majority were located 10-50 kb upstream or downstream of expressed genes, and their position on the genome was conserved in human cells. Old mice displayed the same replication initiation sites, but origin firing was inefficient and accompanied by a replication stress response. Inhibitors of the ATR checkpoint kinase fully restored origin firing efficiency in the old mice but at the expense of an inflammatory response and without significantly enhancing the fraction of hepatocytes entering the cell cycle. These findings unveil aging-dependent replication stress and a crucial role of ATR in mitigating the stress-associated inflammation, a hallmark of aging.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39293447/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">39293447</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.034>10.1016/j.cell.2024.08.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39293447</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Giacomo G Rossetti</dc:creator>
<dc:creator>Noëlle Dommann</dc:creator>
<dc:creator>Angeliki Karamichali</dc:creator>
<dc:creator>Vasilis S Dionellis</dc:creator>
<dc:creator>Ainhoa Asensio Aldave</dc:creator>
<dc:creator>Tural Yarahmadov</dc:creator>
<dc:creator>Eddie Rodriguez-Carballo</dc:creator>
<dc:creator>Adrian Keogh</dc:creator>
<dc:creator>Daniel Candinas</dc:creator>
<dc:creator>Deborah Stroka</dc:creator>
<dc:creator>Thanos D Halazonetis</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>In vivo DNA replication dynamics unveil aging-dependent replication stress</dc:title>
<dc:identifier>pmid:39293447</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.034</dc:identifier>
</item>
<item>
<title>Fine-grained descending control of steering in walking Drosophila</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39293446/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240920061119&amp;v=2.18.0.post9+e462414
      <description>Locomotion involves rhythmic limb movement patterns that originate in circuits outside the brain. Purposeful locomotion requires descending commands from the brain, but we do not understand how these commands are structured. Here, we investigate this issue, focusing on the control of steering in walking Drosophila. First, we describe different limb "gestures" associated with different steering maneuvers. Next, we identify a set of descending neurons whose activity predicts steering. Focusing on...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 13:S0092-8674(24)00962-0. doi: 10.1016/j.cell.2024.08.033. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Locomotion involves rhythmic limb movement patterns that originate in circuits outside the brain. Purposeful locomotion requires descending commands from the brain, but we do not understand how these commands are structured. Here, we investigate this issue, focusing on the control of steering in walking Drosophila. First, we describe different limb "gestures" associated with different steering maneuvers. Next, we identify a set of descending neurons whose activity predicts steering. Focusing on two descending cell types downstream of distinct brain networks, we show that they evoke specific limb gestures: one lengthens strides on the outside of a turn, while the other attenuates strides on the inside of a turn. Our results suggest that a single descending neuron can have opposite effects during different locomotor rhythm phases, and we identify networks positioned to implement this phase-specific gating. Together, our results show how purposeful locomotion emerges from specific, coordinated modulations of low-level patterns.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39293446/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">39293446</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.033>10.1016/j.cell.2024.08.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39293446</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Helen H Yang</dc:creator>
<dc:creator>Bella E Brezovec</dc:creator>
<dc:creator>Laia Serratosa Capdevila</dc:creator>
<dc:creator>Quinn X Vanderbeck</dc:creator>
<dc:creator>Atsuko Adachi</dc:creator>
<dc:creator>Richard S Mann</dc:creator>
<dc:creator>Rachel I Wilson</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Fine-grained descending control of steering in walking Drosophila</dc:title>
<dc:identifier>pmid:39293446</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.033</dc:identifier>
</item>
<item>
<title>Intracellular Ebola virus nucleocapsid assembly revealed by in situ cryo-electron tomography</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39293445/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240920061119&amp;v=2.18.0.post9+e462414
      <description>Filoviruses, including the Ebola and Marburg viruses, cause hemorrhagic fevers with up to 90% lethality. The viral nucleocapsid is assembled by polymerization of the nucleoprotein (NP) along the viral genome, together with the viral proteins VP24 and VP35. We employed cryo-electron tomography of cells transfected with viral proteins and infected with model Ebola virus to illuminate assembly intermediates, as well as a 9 Å map of the complete intracellular assembly. This structure reveals a...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 12:S0092-8674(24)00973-5. doi: 10.1016/j.cell.2024.08.044. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Filoviruses, including the Ebola and Marburg viruses, cause hemorrhagic fevers with up to 90% lethality. The viral nucleocapsid is assembled by polymerization of the nucleoprotein (NP) along the viral genome, together with the viral proteins VP24 and VP35. We employed cryo-electron tomography of cells transfected with viral proteins and infected with model Ebola virus to illuminate assembly intermediates, as well as a 9 Å map of the complete intracellular assembly. This structure reveals a previously unresolved third and outer layer of NP complexed with VP35. The intrinsically disordered region, together with the C-terminal domain of this outer layer of NP, provides the constant width between intracellular nucleocapsid bundles and likely functions as a flexible tether to the viral matrix protein in the virion. A comparison of intracellular nucleocapsids with prior in-virion nucleocapsid structures reveals that the nucleocapsid further condenses vertically in the virion. The interfaces responsible for nucleocapsid assembly are highly conserved and offer targets for broadly effective antivirals.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39293445/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">39293445</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.044>10.1016/j.cell.2024.08.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39293445</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Reika Watanabe</dc:creator>
<dc:creator>Dawid Zyla</dc:creator>
<dc:creator>Diptiben Parekh</dc:creator>
<dc:creator>Connor Hong</dc:creator>
<dc:creator>Ying Jones</dc:creator>
<dc:creator>Sharon L Schendel</dc:creator>
<dc:creator>William Wan</dc:creator>
<dc:creator>Guillaume Castillon</dc:creator>
<dc:creator>Erica Ollmann Saphire</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Intracellular Ebola virus nucleocapsid assembly revealed by in situ cryo-electron tomography</dc:title>
<dc:identifier>pmid:39293445</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.044</dc:identifier>
</item>
<item>
<title>Importance of Prolonged QRS Duration in Detecting Complete Conduction Block</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39292498/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240920061119&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 18. doi: 10.1001/jamacardio.2024.2963. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39292498/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">39292498</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2963>10.1001/jamacardio.2024.2963</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39292498</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Mahbod Rahimi</dc:creator>
<dc:creator>Vijay S Chauhan</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Importance of Prolonged QRS Duration in Detecting Complete Conduction Block</dc:title>
<dc:identifier>pmid:39292498</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2963</dc:identifier>
</item>
<item>
<title>Exploring the Link Between Genetic Predictors of Cardiovascular Disease and Psoriasis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39292496/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240920061119&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Findings of this mendelian randomization study indicate that genetic predictors of cardiovascular disease were associated with increased psoriasis risk with no reciprocal effect or association with other IMIDs. Elucidating mechanisms underpinning this association could lead to novel therapeutic approaches in both diseases.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 18:e242859. doi: 10.1001/jamacardio.2024.2859. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The epidemiological link between immune-mediated diseases (IMIDs) and cardiovascular disease has often been attributed to systemic inflammation. However, the direction of causality and the biological mechanisms linking cardiovascular disease with IMIDs are incompletely understood. Given the robust epidemiological association and the growing body of supportive mechanistic evidence, psoriasis is an exemplary IMID model for exploring this relationship.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess the bidirectional relationships between genetic predictors of psoriasis and the 2 major forms of cardiovascular disease, coronary artery disease (CAD) and stroke, and to evaluate the association between genetic predictors of cardiovascular disease with 9 other IMIDs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a genetic association study using mendelian randomization (MR), a powerful genetic tool to help distinguish causation from associations observed in epidemiological studies, to provide supportive evidence for causality between traits. The study conducted 2-sample MR analyses using summary-level data from large-scale genome-wide association meta-analysis studies (GWAS) for each trait. The analysis focused on individuals of European descent from GWAS meta-analyses, involving CAD, stroke, psoriasis, and 9 other IMIDs. Data were analyzed from January 2023 to May 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Genetic predictors of CAD, stroke, psoriasis, and 9 other IMIDs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcomes were the associations of genetic predictors of CAD and stroke with the risk of psoriasis and 9 other IMIDs, determined using inverse-variance weighted (IVW) MR estimates.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This study included 181 249 cases and 1 165 690 controls with CAD, 110 182 cases and 1 503 898 controls with stroke, 36 466 cases and 458 078 controls with psoriasis, for a total of approximately 3 400 000 individuals, and 9 other IMIDs. In contrast to previous assumptions, genetic predictors of psoriasis were found to have no association with CAD or stroke. In the reverse direction, genetic predictors of both CAD (MR estimate IVW odds ratio [OR], 1.07; 95% CI, 1.04-1.10; P = .003) and stroke (IVW OR, 1.22; 95% CI, 1.05-1.41; P = .01) were found to have risk-increasing associations with psoriasis. Adjusting for stroke rendered the associations of genetically predicted CAD with psoriasis risk nonsignificant (and vice versa), suggesting that a shared effect underlying genetic risk for CAD and stroke associates with increased psoriasis risk. No risk-increasing associations were observed for genetic predictors of cardiovascular disease with other common IMIDs, including rheumatoid arthritis and inflammatory bowel disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Findings of this mendelian randomization study indicate that genetic predictors of cardiovascular disease were associated with increased psoriasis risk with no reciprocal effect or association with other IMIDs. Elucidating mechanisms underpinning this association could lead to novel therapeutic approaches in both diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39292496/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">39292496</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11411451/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240920061119&v=2.18.0.post9+e462414">PMC11411451</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2859>10.1001/jamacardio.2024.2859</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39292496</guid>
<pubDate>Wed, 18 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Ravi Ramessur</dc:creator>
<dc:creator>Jake Saklatvala</dc:creator>
<dc:creator>Ashley Budu-Aggrey</dc:creator>
<dc:creator>Marek Ostaszewski</dc:creator>
<dc:creator>Lena Möbus</dc:creator>
<dc:creator>Dario Greco</dc:creator>
<dc:creator>Matladi Ndlovu</dc:creator>
<dc:creator>Satveer K Mahil</dc:creator>
<dc:creator>Jonathan N Barker</dc:creator>
<dc:creator>Sara Brown</dc:creator>
<dc:creator>Lavinia Paternoster</dc:creator>
<dc:creator>Nick Dand</dc:creator>
<dc:creator>Michael A Simpson</dc:creator>
<dc:creator>Catherine H Smith</dc:creator>
<dc:date>2024-09-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Exploring the Link Between Genetic Predictors of Cardiovascular Disease and Psoriasis</dc:title>
<dc:identifier>pmid:39292496</dc:identifier>
<dc:identifier>pmc:PMC11411451</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2859</dc:identifier>
</item>





























</channel>
</rss>